Clinical trials
Alzheimer clinical trials
Below are recruiting alzheimer clinical trials, each written for real people, not researchers. We’re tracking 633 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06417086Recruiting
Acupuncture for Alzheimer's in gene carriers and non-carriers
This trial tests whether acupuncture can help people with Alzheimer's disease. Researchers will compare results in people who carry the APOE e4 gene and those who don't, to see if the treatment works differently.
ShanghaiAges 50–80 - NCT07066826RecruitingPhase 2/Phase 3
Huperzine A for mild-to-moderate Alzheimer's dementia
This study tests whether Huperzine A controlled-release tablets can help improve memory and thinking in people with mild-to-moderate Alzheimer's disease. You'll take the tablets or a placebo to see if it slows down dementia symptoms.
BeijingAges 50–85 - NCT04800588Recruiting
Computer tests to study early Alzheimer’s changes
This study uses computer and touch-screen tasks to measure thinking changes in people who may be in the early, symptom-free stage of Alzheimer’s disease. It aims to understand how these brain-related changes show up on testing, which could help future detection or tracking.
Berkeley, CaliforniaAges 18–89 - NCT07071649Recruiting
Blood test for Alzheimer's compared with spinal fluid test
This study is testing a simple blood test (p-Tau217) as a possible way to diagnose Alzheimer's disease. If it works, it might replace the need for a spinal tap. The results will be compared with the usual spinal fluid markers.
AmiensAges 18 years+ - NCT07073066Recruiting
Lymphatic surgery for Alzheimer's disease (CLEAN-AD trial)
This trial tests a surgical procedure that connects lymphatic vessels in the neck to help clear waste from the brain in people with moderate-to-severe Alzheimer's disease. The goal is to see if this can improve thinking and memory.
Dongguan, GuangdongAges 50–80 - NCT07058688RecruitingPhase 2
Testing a new drug for Alzheimer's (NTRX-07)
This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.
BrnoAges 65–80 - NCT07062198RecruitingPhase 3
Metabolic supplement for Alzheimer's disease
This trial tests a special supplement combination designed to support brain energy use in people with Alzheimer's. It aims to see if the supplement can help slow cognitive decline.
AlanyaAges 50 years+ - NCT07059871Recruiting
Silkworm powder for nutrition in Alzheimer's disease
This trial tests whether a dietary supplement made from silkworm pupa powder can improve nutrition in people with Alzheimer's disease. It looks at weight, nutrition risk, and daily living skills over time.
Hangzhou, ZhejiangAges 50–90 - NCT07033494RecruitingPhase 2
Study of MK-2214 for early Alzheimer's disease
This trial tests an experimental medicine called MK-2214 for people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow memory and thinking problems.
Irvine, CaliforniaAges 50–85 - NCT07031687Recruiting
A new brain stimulation study for early Alzheimer's
This study tests a non-invasive brain stimulation method (temporal interference stimulation) to see if it can improve memory in people with early signs of Alzheimer's disease. It aims to understand how the stimulation affects brain function.
Sanya, HainanAges 60–80 - NCT03851523Recruiting
Tracking memory changes in people with early Alzheimer’s symptoms
This study follows people over time to better understand how memory and thinking complaints progress in early Alzheimer’s disease (from “subjective cognitive decline” to mild cognitive problems). It may help researchers understand who is likely to decline and how symptoms change, which could support future treatments.
Barcelona, CataloniaAges 45 years+ - NCT07011745RecruitingPhase 3
Study of KarXT for Alzheimer's Agitation
This study tests a new drug combination (KarXT + KarX-EC) to see if it can safely reduce agitation in people with Alzheimer's disease. It may help if you or your loved one has bothersome agitation that affects daily life.
Chandler, ArizonaAges 55–90 - NCT07011732RecruitingPhase 3
Testing a drug for Alzheimer's-related agitation
This study tests an experimental drug (KarXT) to see if it safely reduces agitation in people with Alzheimer's disease. It may help if you or your loved one experiences restlessness, aggression, or irritability related to Alzheimer's.
Scottsdale, ArizonaAges 55–90 - NCT07007208RecruitingPhase 2
Brain imaging study to detect early Alzheimer's risk
This study uses brain scans (MRI and PET) to look at a tiny brain region called the locus coeruleus, which may show early signs of Alzheimer's disease. Researchers want to see if changes in this area are linked to thinking skills and future memory decline.
ToulouseAges 60–100 - NCT06995573RecruitingPhase 1/Phase 2
Testing a new Alzheimer's drug (NSC001) for safety and early effectiveness
This study tests a new drug called NSC001 for people with mild to moderate Alzheimer's. It checks if the drug is safe and if it might help slow memory decline. You'll need a caregiver who can join you at visits and help track your progress.
Salzburg, State of SalzburgAges 50–85 - NCT06992804RecruitingEarly Phase 1
Light therapy and lecanemab for mild Alzheimer's
This trial tests whether a special near-infrared light device, combined with the medication lecanemab, can help people with mild Alzheimer's disease. It aims to see if the light therapy can slow down memory loss and improve daily function.
BeijingAges 50–90 - NCT06827678Recruiting
Study of Alzheimer’s disease using brain scans in China
This study uses brain imaging to understand early changes in Alzheimer's disease. It may help people with or without memory problems learn more about their condition and support future treatments.
ShanghaiAges 45–90 - NCT06976216RecruitingPhase 3
Study of KarXT plus KarX-EC for Alzheimer's cognitive symptoms
This trial tests a new combination treatment (KarXT plus KarX-EC) to see if it can help with thinking and memory problems caused by Alzheimer's disease. It is for people with mild to moderate Alzheimer's who have a caregiver available.
Long Beach, CaliforniaAges 60–85 - NCT06976203RecruitingPhase 3
Testing karxt for thinking problems in alzheimer's
This trial tests if a combination medicine, KarXT plus KarX-EC, can help with thinking and memory problems in people with mild to moderate Alzheimer's disease. It aims to see if the treatment is safe and effective.
Fullerton, CaliforniaAges 60–85 - NCT06923007Recruiting
Vagus nerve stimulation for Alzheimer's disease
This trial tests if a nerve stimulation device can help people with mild to moderate Alzheimer's. It is for patients aged 50 to 80 who are on a stable medication.
BeijingAges 50–80 - NCT06963879Enrolling by invitation
Video game test and treatment for Alzheimer's disease
This study uses interactive video games to help diagnose and potentially treat early-stage Alzheimer's disease or mild cognitive impairment. It is testing whether these games can improve thinking skills.
Mataró, BarcelonaAges 50 years+ - NCT06956300Recruiting
TMS to help with thinking and memory in aging
This study uses a noninvasive brain stimulation technique called TMS to see if it can slow cognitive decline in older adults who are healthy or have very early signs of Alzheimer's disease. It aims to improve memory and thinking.
Boston, MassachusettsAges 40–99 - NCT06948929Recruiting
Gut health supplement trial for Alzheimer's patients in Hong Kong
This trial tests whether a daily supplement of friendly bacteria and prebiotics (called a synbiotic) can help people with Alzheimer's. It looks at how the supplement affects thinking, behavior, and daily life over time.
ShatinAges 60–90 - NCT06947941RecruitingPhase 3
Testing karxt for psychosis in alzheimer's disease
This study tests whether a new medicine called KarXT can help with psychosis (hallucinations or delusions) in people with Alzheimer's disease. It aims to reduce troubling symptoms while being safe for older adults.
Gilbert, ArizonaAges 55–90
Hear when a new Alzheimer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alzheimer?
- Yes. Clin2 currently lists 633 recruiting alzheimer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alzheimer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alzheimer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.